Author:
List Alan F.,Glinsmann-Gibson Betty,Dalton William S.
Publisher
Springer Berlin Heidelberg
Reference39 articles.
1. List AF: Multidrug resistance and its clinical relevance in acute leukemia. Oncology 7: 23–32, 1993.
2. Pirker R, Wallner J, Geissler K, et al.: mdr1 gene expression and treatment outcome in acute myeloid leukemia. J Natl Cancer Inst 83: 708–712, 1991.
3. Campos L, Guyotat T, Archimbaud E, et al.: Clinical significance of multidrug resistance P-glycoprotein expression on acute nonlymphoblastic leukemia cells at diagnosis. Blood 79: 473–476, 1992.
4. Willman CL, Kopecky K, Weick J, et al. Riologic parameters that predict treatment response in de novo acute myeloid leukemia (AML): CD34, but not multidrug resistance (MDR) gene expression, is associated with a decreased complete remission (CR) rate and CD34+ patients more frequently achieve CR with high dose cytosine arabinoside. Proc Am Soc Clin Oncol 1992; 11: 262a.
5. List AF, Spier CM, Cline A, et al. Expression of the multidrug resistance gene product (P-glycoprotein) in myelodysplasia is associated with a stem cell phenotype. Br J Haematol 1991; 78: 28–34.